MAP2K7 and myelofibrosis: Another strategy that is in line with the concept of synergistic targeting but is more relevant to the known existing therapeutic landscape in myelofibrosis is combining Mek (or other agents targeting MAP Kinase pathway signaling) with Jak inhibitors to manage resistance to Jak inhibitor monotherapies.